JP2023521875A5 - - Google Patents
Info
- Publication number
- JP2023521875A5 JP2023521875A5 JP2022562606A JP2022562606A JP2023521875A5 JP 2023521875 A5 JP2023521875 A5 JP 2023521875A5 JP 2022562606 A JP2022562606 A JP 2022562606A JP 2022562606 A JP2022562606 A JP 2022562606A JP 2023521875 A5 JP2023521875 A5 JP 2023521875A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- population
- modified
- akt inhibitor
- akt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2005617.2 | 2020-04-17 | ||
| GBGB2005617.2A GB202005617D0 (en) | 2020-04-17 | 2020-04-17 | Improved t cell manufacturing process |
| PCT/GB2021/050909 WO2021209759A1 (en) | 2020-04-17 | 2021-04-16 | Improved t cell manufacturing process |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023521875A JP2023521875A (ja) | 2023-05-25 |
| JP2023521875A5 true JP2023521875A5 (https=) | 2024-04-25 |
| JP7760524B2 JP7760524B2 (ja) | 2025-10-27 |
Family
ID=70859978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022562606A Active JP7760524B2 (ja) | 2020-04-17 | 2021-04-16 | 改善されたｔ細胞製造プロセス |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230133064A1 (https=) |
| EP (1) | EP4136216A1 (https=) |
| JP (1) | JP7760524B2 (https=) |
| CN (1) | CN115397975A (https=) |
| CA (1) | CA3175266A1 (https=) |
| GB (1) | GB202005617D0 (https=) |
| WO (1) | WO2021209759A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2973548T3 (es) | 2016-12-22 | 2024-06-20 | Cue Biopharma Inc | Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso |
| EP3565829A4 (en) | 2017-01-09 | 2021-01-27 | Cue Biopharma, Inc. | T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF |
| US20200010528A1 (en) | 2017-03-15 | 2020-01-09 | Cue Biopharma, Inc. | Methods for modulating an immune response |
| WO2021231376A2 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| WO2022056014A1 (en) | 2020-09-09 | 2022-03-17 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof |
| CN116496283B (zh) * | 2022-01-18 | 2024-04-19 | 中国药科大学 | 五氮杂苊类化合物、制备方法、药物组合物和应用 |
| EP4514835A4 (en) * | 2022-04-28 | 2026-04-15 | Cue Biopharma Inc | MODIFIED CYTOXIC T LYMPHOCYTES AND ASSOCIATED METHODS OF USE |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3151672T1 (sl) * | 2014-06-06 | 2021-03-31 | Bluebird Bio, Inc. | Izboljšani T-celični sestavki |
| WO2017070042A1 (en) * | 2015-10-20 | 2017-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing t cell populations using akt inhibitors |
| KR20180063320A (ko) * | 2015-10-20 | 2018-06-11 | 카이트 파마 인코포레이티드 | T 세포 요법을 위한 t 세포를 제조하는 방법 |
| CA3004299A1 (en) * | 2015-11-05 | 2017-05-11 | City Of Hope | Methods for preparing cells for adoptive t cell therapy |
-
2020
- 2020-04-17 GB GBGB2005617.2A patent/GB202005617D0/en not_active Ceased
-
2021
- 2021-04-16 JP JP2022562606A patent/JP7760524B2/ja active Active
- 2021-04-16 CN CN202180029152.2A patent/CN115397975A/zh active Pending
- 2021-04-16 WO PCT/GB2021/050909 patent/WO2021209759A1/en not_active Ceased
- 2021-04-16 EP EP21721165.5A patent/EP4136216A1/en active Pending
- 2021-04-16 CA CA3175266A patent/CA3175266A1/en active Pending
-
2022
- 2022-10-14 US US18/046,874 patent/US20230133064A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023521875A5 (https=) | ||
| US20230092130A1 (en) | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof | |
| JP7524249B2 (ja) | 抗癌治療における組み合わせ使用のためのメソテリンキメラ抗原受容体（ｃａｒ）およびｐｄ－ｌ１阻害剤に対する抗体 | |
| JP7134204B2 (ja) | キメラ受容体及びその使用方法 | |
| TWI719942B (zh) | 使用ｃｄ３３嵌合抗原受體治療癌症 | |
| RU2756247C2 (ru) | Генетически модифицированные гамма дельта т-клетки | |
| JP2022166049A (ja) | キメラ抗原受容体をキナーゼ阻害薬と併用して使用したサイトカイン放出症候群の治療及び予防 | |
| CA3118493A1 (en) | Expansion of tils utilizing akt pathway inhibitors | |
| TW202134285A (zh) | Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途 | |
| JP2021526814A5 (https=) | ||
| CA3118616A1 (en) | Selection of improved tumor reactive t-cells | |
| TW201930591A (zh) | 用於與嵌合抗原受體療法併用之免疫增強rna | |
| UA126281C2 (uk) | Антитіла проти сигнал-регуляторного білка альфа та способи їх застосування | |
| KR20220038439A (ko) | 자연 살해 세포의 향상된 증폭 및 세포 독성을 위한 방법 및 조성물 | |
| BR112020018670A2 (pt) | Receptor de antígeno quimérico de receptor alfa 2 da il-13 (il13ra2) para imunoterapia com células t específicas para tumor | |
| CA3123392A1 (en) | Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof | |
| BR112021002579A2 (pt) | novas construções de car compreendendo os domínios de tnfr2 | |
| JP2022520871A (ja) | ナチュラルキラー細胞およびキメラ抗原受容体改変された細胞の拡大増殖 | |
| JP2024527559A5 (https=) | ||
| JP2018506995A5 (https=) | ||
| TW202304480A (zh) | 腫瘤浸潤淋巴球（ｔｉｌ）中之與ｃｄ３９／ｃｄ６９選擇及基因剔除相關之ｔｉｌ擴增之方法 | |
| JP2022522231A5 (https=) | ||
| WO2020214650A1 (en) | Methods and compositions for modulating the immune system | |
| JP2024542159A5 (https=) | ||
| AU2018370120A1 (en) | Methods for selective expansion of d3 yd T-cell populations and compositions thereof |